Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
Powles T, Peters J, Boleti K, Nathan P, Wilson P, Sadev A, Sarwar N, Lim L, Saunders N, Gillessen Sommer S, Bazeos A, Shamash J, Chowdhury S, Agrawal S. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Ann Oncol 2010
Oct 13, 2010Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
Oct 13, 2010Ann Oncol 2010
Powles T, Peters J, Boleti K, Nathan P, Wilson P, Sadev A, Sarwar N, Lim L, Saunders N, Gillessen Sommer Silke, Bazeos A, Shamash J, Chowdhury S, Agrawal S
[Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]
Thürlimann B. [Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]. Praxis (Bern 1994) 2010; 99:1217-8.
Oct 6, 2010[Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]
Oct 6, 2010Praxis (Bern 1994) 2010; 99:1217-8
Thürlimann Beat
Prevalence of burnout among surgical residents and surgeons in Switzerland
Businger A, Stefenelli U, Gueller U. Prevalence of burnout among surgical residents and surgeons in Switzerland. Arch Surg 2010; 145:1013-6.
Oct 1, 2010Prevalence of burnout among surgical residents and surgeons in Switzerland
Oct 1, 2010Arch Surg 2010; 145:1013-6
Businger Adrian, Stefenelli Ulrich, Gueller Ulrich
[New treatments of malignant lymphoma--a review]
Mark M, Cerny T. [New treatments of malignant lymphoma--a review]. Ther Umsch 2010; 67:537-43.
Oct 1, 2010[New treatments of malignant lymphoma--a review]
Oct 1, 2010Ther Umsch 2010; 67:537-43
Mark Michael, Cerny Thomas
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Mouridsen H, Thürlimann B, Robidoux A, Llombart-Cussac A, Gligorov J, Doughty J, Blackwell K, Beckmann M, Lønning P, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.
Sep 30, 2010Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Sep 30, 2010Expert Rev Anticancer Ther 2010; 10:1825-1836
Mouridsen Henning T, Thürlimann Beat, Robidoux Andre, Llombart-Cussac Antonio, Gligorov Joseph, Doughty Julie, Blackwell Kimberly, Beckmann Matthias W, Lønning Per, Gnant Michael
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
Sep 20, 2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Sep 20, 2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
Sep 13, 2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Sep 13, 2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel I, Untch M, Roller M, Eulenburg C, Barinoff J, Hilfrich J, Just M, Latos K, Tesch H, Lantzsch T, Hauschild M, Henschen S, Hanusch C, Huober J, Mundhenke C, von Minckwitz G, Loibl S, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123:437-45.
Sep 1, 2010Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Sep 1, 2010Breast Cancer Res Treat 2010; 123:437-45
Witzel Isabell, Untch Michael, Roller Marc, Eulenburg Christine Zu, Barinoff Jana, Hilfrich Jörn, Just Marianne, Latos Kunibert, Tesch Hans, Lantzsch Tilmann, Hauschild Maik, Henschen Stephan, Hanusch Claus, Huober Jens, Mundhenke Christoph, von Minckwitz Gunter, Loibl Sibylle, Müller Volkmar
Invasive palliative interventions: when are they worth it and when are they not?
Strasser F, Blum D, Büche D. Invasive palliative interventions: when are they worth it and when are they not?. Cancer J 2010; 16:483-7.
Sep 1, 2010Invasive palliative interventions: when are they worth it and when are they not?
Sep 1, 2010Cancer J 2010; 16:483-7
Strasser Florian, Blum David, Büche Daniel
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Engelhardt M, Straka C, Johnsen H, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Kropff M, Sezer O, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón J, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010; 51:2006-11.
Aug 31, 2010European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Aug 31, 2010Leuk Lymphoma 2010; 51:2006-11
Engelhardt Monika, Straka Christian, Johnsen Hans E, Waage Anders, Boegsted Martin, Lokhorst Henk, Hájek Roman, Morgan Gareth, Boccadoro Mario, Ludwig Heinz, Cavo Michele, Polliack Aaron, Sonneveld Pieter, Einsele Hermann, Kropff Martin, Sezer Orhan, Udi Josefina, Kleber Martina, Spencer Andrew, Rocci Alberto, Knop Stefan, Bruno Benedetto, Bringhen Sara, Pérez-Simón José A, Zweegman Sonja, Driessen Christoph, Patriarca Francesca, Gramatzki Martin, Terpos Evangelos, Palumbo Antonio
What is the value of the 21-gene recurrence score?
Brauchli P, Thürlimann B, Crowe S, Herrmann R. What is the value of the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.
Aug 30, 2010What is the value of the 21-gene recurrence score?
Aug 30, 2010J Clin Oncol 2010; 28:e671-2
Brauchli Peter, Thürlimann Beat, Crowe Susanne N, Herrmann Richard
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
du Bois A, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Kurzeder C, Weber B, Herrstedt J, Hardy-Bessard A, Müller H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162-9.
Aug 23, 2010Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Aug 23, 2010J Clin Oncol 2010; 28:4162-9
du Bois Andreas, Jelic Svetislav, Pujade-Lauraine Eric, Burges Alexander, Pfisterer Jacobus, Gropp Martina, Staehle Anne, Wimberger Pauline, Jackisch Christian, Kurzeder Christian, Weber Béatrice, Herrstedt Jørn, Hardy-Bessard Anne-Claire, Müller Hans-Helge, Harter Philipp, Kristensen Gunnar, Joly Florence, Huober Jens, Avall-Lundqvist Elisabeth, Sehouli Jalid
Predictors of state-of-the-art management of early breast cancer in Switzerland
Ess S, Jörger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
Aug 12, 2010Predictors of state-of-the-art management of early breast cancer in Switzerland
Aug 12, 2010Ann Oncol 2010; 22:618-24
Ess S, Jörger Markus, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann Beat
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Huober J, Mehta K, Darb-Esfahani S, Högel B, Thomssen C, Hauschild M, Khandan F, Belau A, Zahm D, Weiss E, Tesch H, Denkert C, von Minckwitz G, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-40.
Aug 10, 2010Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Aug 10, 2010Breast Cancer Res Treat 2010; 124:133-40
Huober Jens, Mehta Keyur, Darb-Esfahani Silvia, Högel Bernhard, Thomssen Christoph, Hauschild Maik, Khandan Fariba, Belau Antje, Zahm Dirk Michael, Weiss Erich, Tesch Hans, Denkert Carsten, von Minckwitz Gunter, Loibl Sibylle
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
Aug 9, 2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Aug 9, 2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
New Developments in Breast Cancer Therapy Presented at ASCO 2010
Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G. New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care (Basel) 2010; 5:266-271.
Aug 9, 2010New Developments in Breast Cancer Therapy Presented at ASCO 2010
Aug 9, 2010Breast Care (Basel) 2010; 5:266-271
Müllera Volkmar, Dubsky Peter, Fehm Tanja, Fitzal Florian, Huober Jens, Schmidt Marcus, Steger Günther
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
Langer I, Gueller U, Viehl C, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Indian J Surg Oncol 2010; 1:59-67.
Aug 7, 2010Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
Aug 7, 2010Indian J Surg Oncol 2010; 1:59-67
Langer Igor, Gueller Ulrich, Viehl Carsten T, Moch Holger, Wight Edward, Harder Felix, Oertli Daniel, Zuber Markus
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010
Aug 4, 2010Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Aug 4, 2010Cancer Chemother Pharmacol 2010
Jörger Markus, Templeton Arnoud, Köberle Dieter, Engler H, Riesen W F, Thürlimann Beat
Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jörger M, Riesen W, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010
Jul 28, 2010Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jul 28, 2010J Oncol Pharm Pract 2010
Jörger Markus, Riesen W F, Thürlimann Beat
Metastasiertes Nierenzellkarzinom - Moderne Behandlung bei fortgeschrittenem Stadium
Templeton A, Rothermundt C. Metastasiertes Nierenzellkarzinom - Moderne Behandlung bei fortgeschrittenem Stadium. Ars Medici 2010; 15:598-602.
Jul 26, 2010Metastasiertes Nierenzellkarzinom - Moderne Behandlung bei fortgeschrittenem Stadium
Jul 26, 2010Ars Medici 2010; 15:598-602
Templeton Arnoud, Rothermundt Christian